
-
Viking Therapeutics NasdaqCM:VKTX Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Location: 9920 Pacific Heights Boulevard, San Diego, CA, 92121, United States | Website: https://www.vikingtherapeutics.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.312B
Cash
851.9M
Avg Qtr Burn
-33.5M
Short % of Float
23.25%
Insider Ownership
2.12%
Institutional Own.
70.16%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
VK2735 (Injectable) Details Metabolic disorder, Obesity | Phase 3 Initiation | |
VK2809 Details Non-alcoholic steatohepatitis | Phase 2b Update | |
VK2735 (Oral formulation) Details Metabolic disorder, Obesity | Phase 2 Data readout | |
VK0214 Details X-linked adrenoleukodystrophy | Phase 1b Update | |
VK5211 (SARM) Details Muscle injury following hip fracture | Failed Discontinued |